ARCHIVES

ACCP and ASCO Publish Joint Guideline Following Review of Evidence on Low-Dose CT

This article is from The Cancer Letter archive.

Vol. 35 No. 5 | May 25, 2012

Download PDF Visit The Full Archive

Related Articles

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

December 30, 2011

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

May 22, 1981

Scientists, Public Citizen Urge FDA To Ban Sale Of Obesity Drug Orlistat.

June 2, 2006

ACS Challenged To Clarify Position On FDA Reform

March 1, 1996

SBIR Solicitation Issued

September 13, 1996

Trials Approved by NCI CTEP For the Month of May

May 25, 2012